Repligen Corp (RGEN) - News Archive

Repligen’s Strategic Acquisition: A New Chapter in Bioprocessing Analytics In a noteworthy development within the biopharmaceutical sector, Repligen Corporation has recently announced the acquisition of an esteemed biop...

In an exciting development for the biopharmaceutical industry, Repligen Corporation has inaugurated its Training and Innovation Center (RTIC), marking a significant commitment to elevating customer experience and foster...

In a strategic move poised to redefine the landscape of bioprocessing technology, Repligen Corporation (NASDAQ:RGEN), a leading life sciences company from Waltham, Massachusetts, announced on July 29, 2024, its definiti...

Introducing DurA Cycle Affinity Resin: A Game-Changer in Large-Scale Biologic Manufacturing ST. PAUL, Minn. & WALTHAM, Mass. - Ecolab, a leader in solutions for water, hygiene, and energy technologies, and Repligen Corp...

Repligen Corporation, a leading biotechnology and pharmaceutical company, has recently made a significant announcement regarding a private convertible transaction. On December 6, 2023, Repligen entered into privately ne...